Region Stockholm

regionstockholm.se

Total trials

114

Active

75

Phase 3

3

Total enrollment

3,656,827

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 16 of 16 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Apixaban 2.5 milligram Oral1
5U/0,1 ml Botulinum toxin A1
10U/0,1 ml Botulinum toxin A1
Dapagliflozin 10 mg once daily1
Roxadustat1
Darbepoietin Alfa1
Lithium1
Anti-CD20 Monoclonal Antibody1
IEM-EP1
monoclonal CD-20 antibodies1
No Drug1
Other treatment1
High Flow Oxygen1
Oxygen1
Induced hypertension with norepinephrine1
Endoluminal Spasmolysis1

Next readouts

  • 2025-12
  • 2026-12-01
  • 2027-01-01
  • 2027-10
  • 2027-12
  • 2027-12-31
  • 2028-03-09
  • 2029-12-31
  • 2030-08-31
  • 2030-12-31

Top conditions

  • Endometriosis3
  • Clubfoot3
  • Heart Failure3
  • Depression3
  • Cerebral Palsy2
  • Cardiovascular Diseases2
  • Psychiatric Inpatients2
  • Multiple Sclerosis2

Frequently asked questions about Region Stockholm

How many clinical trials does Region Stockholm have on ClinicalTrials.gov?
Region Stockholm is listed as the lead sponsor on 114 clinical trials in ClinicalTrials.gov, 75 of which are currently active (recruiting, enrolling, or ongoing).
How many of Region Stockholm's trials are in Phase 3?
3 of Region Stockholm's trials are in Phase 3, spread across 16 active drug programs.
What therapeutic areas does Region Stockholm focus on?
Region Stockholm's most-studied conditions on ClinicalTrials.gov are Endometriosis, Clubfoot, Heart Failure, Depression, Cerebral Palsy.
When are Region Stockholm's next clinical trial readouts?
Region Stockholm has 10 upcoming primary-completion readouts tracked here; the soonest is “B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment”, expected around 2025-12.